(+/-) 6-acetoxy-2,5,7,8 tetramethylchroman-2-carboxylic acid chloride | 54154-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (+/-) 6-acetoxy-2,5,7,8 tetramethylchroman-2-carboxylic acid chloride
• 英文别名: 6-acetoxy-2,5,7,8-tetramethylchroman-2-carboxylic acid chloride；2-(chlorocarbonyl)-2,5,7,8-tetramethylchroman-6-yl acetate；(2-carbonochloridoyl-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl) acetate
• CAS: 54154-19-7
• 化学式: C₁₆H₁₉ClO₄
• 分子量: 310.777
• InChiKey: XXFLYELFTZOCRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  404.6±45.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+/-) 6-acetoxy-2,5,7,8 tetramethylchroman-2-carboxylic acid chloride 在 silver nitrate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 24.0h， 生成 [2,5,7,8-Tetramethyl-2-(2-nitrooxyethylcarbamoyl)-3,4-dihydrochromen-6-yl] acetate
  参考文献：
  名称：

  Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs

  摘要：

  Synthesis and biological characterization of a series of alpha-tocopherol analogs with NO-releasing capacity are reported. The selected NO-donor moieties were nitrooxy and furoxan. All products were tested for their in vitro NO-releasing capacities, vasodilating properties, and antiplatelet activity. They were also capable of preventing LDL oxidation. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.05.060
• 作为产物：
  描述：

  6-acetoxy-2,5,7,8-tetramethylchromane-2-carboxylic acid 以 氯苯 为溶剂， 生成 (+/-) 6-acetoxy-2,5,7,8 tetramethylchroman-2-carboxylic acid chloride
  参考文献：
  名称：

  Antioxidant chroman compounds

  摘要：

  (6-羟基-色苷-2-基) 乙酸或羧酸衍生物可用作抗氧化剂，以及从对苯二酚和合成中间体制备这些衍生物的方法，以及在制备光学活性α-生育酚中使用这些衍生物作为中间体。

  公开号：

  US03947473A1

文献信息

• 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
  申请人：Jankowski Orion D.

  公开号：US20090118257A1

  公开（公告）日：2009-05-07

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  揭示了治疗或抑制线粒体疾病的方法，例如弗里德雷希共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒和中风（MELAS）、科恩斯-萨耶综合征（KSS），以及在本发明方法中有用的化合物，如4-(对喹啉基)-2-羟基丁酰胺衍生物。还揭示了用于治疗其他疾病的方法和化合物，如肌萎缩侧索硬化症（ALS）、亨廷顿病、帕金森病和广泛性发展障碍如自闭症。还揭示了用于评估受试者代谢状态和治疗疗效的能量生物标志物。还揭示了调节、规范或增强能量生物标志物的方法，以及用于这些方法的化合物。
• Preparation Of Phenol-Amide Compounds With Anti-Oxidizing Properties
  申请人：Adrian Guy

  公开号：US20070281991A1

  公开（公告）日：2007-12-06

  The invention relates to the preparation of compounds comprising at least one phenol function and one amide function derived from amino-2-alkanol-1 having formula (I) and (II), which have antioxidant and an tiradical properties and which are soluble in lipid media. The inventive compounds can be used as cosmetic or pharmaceutical preparations for the prevention of biological degradation caused by free radicals.

  本发明涉及制备化合物，该化合物包含至少一个苯酚基和一个源自氨基-2-烷醇-1的酰胺基，其具有抗氧化和抗自由基的特性，并且在脂质介质中可溶。这些化合物可用作化妆品或药物制剂，用于预防自由基引起的生物降解。
• 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
  申请人：Edison Pharmaceuticals, Inc.

  公开号：US07968746B2

  公开（公告）日：2011-06-28

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，如弗里德赫氏共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒和中风（MELAS）、基恩斯-塞尔综合症（KSS），以及在本发明方法中有用的化合物，如4-(p-喹啉基)-2-羟基丁酰胺衍生物。本发明还公开了治疗其他疾病，如肌萎缩性侧索硬化症（ALS）、亨廷顿病、帕金森病和广泛性发育障碍，如自闭症的方法和化合物。本发明还公开了用于评估受试者代谢状态和治疗效果的能量生物标志物。本发明还公开了调节、规范或增强能量生物标志物的方法，以及用于此类方法的化合物。
• 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
  申请人：PTC Therapeutics, Inc.

  公开号：US10968166B2

  公开（公告）日：2021-04-06

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinoly)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，如弗里德雷氏共济失调（FRDA）、勒伯氏遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒和中风（MELAS）、卡恩斯-赛尔综合征（KSS），以及用于本发明方法的化合物，如4-（对-喹啉基）-2-羟基丁酰胺衍生物。本发明还公开了用于治疗其他疾病的方法和化合物，如肌萎缩性脊髓侧索硬化症（ALS）、亨廷顿氏病、帕金森氏病和广泛性发育障碍，如自闭症。还公开了有助于评估受试者代谢状态和治疗效果的能量生物标记物。还公开了调节、正常化或增强能量生物标志物的方法以及用于此类方法的化合物。
• 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2220030A2

  公开（公告）日：2010-08-25